Reportlinker Adds Biobanking for Medical R&D: Technology and Market 2010-2025
NEW YORK, Oct. 7 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biobanking for Medical R&D: Technology and Market 2010-2025
http://www.reportlinker.com/p0306323/Biobanking-for-Medical-RD-Technology-and-Market-2010-2025.html
Report Details
– how will biobanking develop and contribute to healthcare? Our new report explains its prospects
Do you want to know the prospects for biobanking in medical research, pharmaceutical R&D and personalised medicine? Our new study shows you its technological and commercial potential. You can have that report today, staying ahead. Demand for biobanking has been expanding. There will be commercial growth, with important trends to watch from 2010 onwards.
Our report shows how you can benefit. As the pharmaceutical industry shifts towards personalised medicine, there is a need for usable, well-maintained biospecimen collections. We show you where the biobanking sector is heading, forecasting its technological and commercial potential from 2010 onwards.
Biobanking for Medical R&D: Technology and Market 2010-2025 reveals the opportunities and challenges the biobanking sector will face. These include consolidation and harmonisation of biobanking practices. Advances in genetic research, stem cell research and regenerative medicine increase the importance of biobanking, as well as its commercial potential.
Our report provides data on current and future revenue values for the biobanking sector, globally and nationally. You will find that information only there. We cover both the for-profit and non-profit sectors. We analyse strengths, weaknesses and revenue trends for biobanking from 2010 to 2025. You can discover the sector's prospects today.
Biobanked collections are increasingly valued by medical researchers and drug developers worldwide. What are the potential benefits to the pharma industry? How will biobanking product and service providers benefit? Our new report gives you answers and trends, saving you time and aiding your decisions.
Analysis of the world biobanking industry and market to meet your needs
Our new report examines the biobanking sector for medical R&D critically. We harness primary and secondary research to meet your needs. We provide revenue forecasts, market share analyses and other data. You will discover market strengths, weaknesses, opportunities and threats. We include over 45 tables and figures and an expert interview, as shown in the lists that follow. This is a market- and industry-centred study, with analyses and opinion to benefit your work.
Why you should buy Biobanking for Medical R&D: Technology and Market 2010-2025
Our report gives you the following benefits in particular:
• You will receive hard data for the biobanking sector – and much more – including our revenue predictions from 2010 to 2025
• You will receive analyses for the overall market and its main components
• You will read the first report of its kind, one providing insight into the biobanking industry and market, helping you to stay ahead
• You will find out the potential revenues in leading national markets (US, Germany, France, Italy, Spain, UK, Japan, India and China) from 2010 to 2025
• You will assess leading organisations in biobanking, discovering their activities and prospects
• You will find out where biobanking is heading – technologically and commercially – from 2010 onwards
• You will discover the drivers, restraints, competition and opportunities influencing the biobanking sector
• You will discover expert views from our survey.
With our report, you can assess that emerging sector, aiding your decisions and saving time.
You can have this report today
Our new report can benefit everybody interested in healthcare biotechnology. We reveal prospects for biobanking from the present onwards. Do you want to harness those opportunities? You can stay ahead by ordering our report now.
Table of Contents
1. Executive Summary
1.1 Summary Points
1.2 Aims, Scope and Format of this Report
1.2.1 Speculative Aspects of Assessing the Biobanking Market
1.2.2 Chapter Outlines
1.3 Research and Analysis Methods
2. Introduction to Biobanking
2.1 Biobanking
2.1.1 Processes Involved in Biobanking
2.2 Biobanks: A Two-fold Character
2.3 Key Features
2.4 Classification of Biobanks
2.4.1 Volunteer Groups
2.4.1.1 Population-based Biobanks
2.4.1.2 Disease-oriented Biobanks
2.4.2 Ownership or Funding Structure
2.5 Guidelines and Standards
2.5.1 Guidelines for Biobanks and Use of Biological Samples for Research
2.5.2 Industry Standards for Biobanks
2.5.3 Biobanking Processes Governed by Guidelines
2.6 Laws and Regulations for Biobank-based Research
3. Biobanking and the Pharmaceutical Industry
3.1 Scientific and Commercial Use of Biobanking in the Pharmaceutical Industry
3.1.1 Research and Drug Development
3.1.1.1 Understanding Disease Pathways
3.1.1.2 Drug Discovery
3.1.1.3 Biomarker Discovery
3.1.2 Therapeutics
3.1.3 Clinical Trials
3.2 Biobanks Operated by Pharmaceutical Companies
4. Biobanking: Associated Market (Systems, Software, Consumables, and Services Associated with Biobanking)
4.1 Systems/ Technologies
4.1.1 Automated Liquid Handling
4.1.1.1 Frozen Aliquotting: New Technology in Development
4.1.2 Storage
4.1.2.1 Ultra-low Temperature Freezing
4.1.2.2 Room-Temperature Storage
4.1.3 RFID and Tagging Technologies
4.2 Software
4.2.1 Laboratory Information Management System (LIMS)
4.2.1.1 LIMS Functions
4.3 Consumables
4.4 Services
5. Global Biobanking Market, 2010-2025
5.1 Current State of the Biobanking Market
5.2 Geographical Footprint
5.3 Growing Demand for Biobank Resources
5.4 Revenue Forecast for Total Biobanking Market
5.4.1 Scope and Limitations
5.4.2 Biobanking Market, 2010-2025
5.5 Commercial Biobanks: New Resources for Research
6. Human Tissue Banking Market
6.1 Revenue Forecast for Total Human Tissue Banking Market, 2010-2025
6.2 Revenue Forecasts for Human Tissue Banking Market by Type of Biobank, 2010-2025
6.3 Revenue Forecasts for Human Tissue Banking in Leading National Markets, 2010-2025
6.4 Commercial Participants in the Human Tissue Banking Market
6.4.1 Business Models of Companies in the Biobanking Market
6.4.2 Tissue Solutions Ltd.
6.4.2.1 Overview
6.4.2.2 Global Presence
6.4.2.3 Products and Services
6.4.2.3.1 Banked Samples
6.4.2.3.2 Prospective Samples
6.4.2.3.3 Fresh Samples
6.4.2.3.4 Freshly Isolated and Primary Cells
6.4.2.3.5 Services
6.4.2.4 Strengths and Capabilities
6.4.2.5 Future Outlook
6.4.3 Asterand Plc.
6.4.3.1 Overview
6.4.3.2 Global Presence
6.4.3.3 Products and Services
6.4.3.3.1 XpressBANK
6.4.3.3.2 ProCURE
6.4.3.3.3 PhaseZERO
6.4.3.3.4 BioMAP
6.4.3.4 Asterand: Providing Barriers for New Market Entrants?
6.4.3.5 Financial Performance
6.4.3.6 Future Outlook
7. Stem Cell Banking
7.1 Overview
7.2 Revenue Forecast for Total Stem Cell Banking, 2010-2025
7.3 Stem Cell Banks for Research: High Growth Possible
7.4 Umbilical Cord Blood Banking for Stem Cells
7.4.1 Biological Insurance: Private Blood Banking
7.4.2 Umbilical Cord Banking: The Controversies
7.4.2.1 US Oversight of Cord Blood Stem Cells
7.4.3 Companies in the Field
7.4.3.1 Cord Blood America: Looking Towards the Chinese Market
7.4.3.2 ViaCord: 145,000 Blood Units in Storage
7.4.3.3 Cryo-Cell International: The First Cord Blood Bank
7.4.3.4 Stem Cell Authority: Exclusive Stem Cells
7.4.3.5 LifebankUSA: Placenta-Cord Banking
7.5 Gene/ DNA Banking
8. Industry Trends
8.1 Automated Biobanking
8.1.1 Increased Uptake of Laboratory Information Management Systems (LIMS) in Biobanking
8.1.2 Addressing Sample Storage and Tracking Issues
8.2 Green Banking
8.3 Creation of National Biobanks
8.4 HIPAA Amendments
9. SWOT Analysis of the Biobanking Sector
9.1 Strengths
9.1.1 Wealth of Information for Genetic Research
9.1.2 Potential to Change Treatments
9.1.3 Many Governments Support Biobanking
9.2 Weaknesses
9.2.1 Quality Concerns for Existing Biospecimen Collections
9.2.2 Lack of Standardisation and Harmonisation of Best Practices
9.2.3 Limited Sharing and Linkage of Biobanks
9.3 Opportunities
9.3.1 Genome-Wide Association Studies (GWAS)
9.3.2 Personalised Medicine
9.3.3 Pharmacogenomics: Driving the Personalised Medicine Approach
9.4 Threats
9.4.1 Ethical and Regulatory Issues
9.4.1.1 Limitations of Informed Consent in Biobanking
9.4.1.2 Confidentiality and Security to Prevent Improper Use
9.4.2 Social and Cultural Issues
9.4.3 Ownership Issues
9.4.4 Funding
10. Expert Opinion
10.1 Dr Morag McFarlane, Chief Scientific Officer, Tissue Solutions
10.1.1 On the Use of Biobank Samples in the Pharmaceutical Industry
10.1.2 On Commercial Aspects of Biobanking
10.1.3 On the Business of Tissue Solutions
10.1.4 On the Attractiveness of Human Tissue Banking
10.1.5 On the Future of the Biobanking Market
11. Conclusions
11.1 Biobanking for Research and Therapeutics
11.2 Biobanking: The Future for Drug Discovery and Personalised Medicine?
11.3 Commercial Drivers of the Biobanking Market
11.4 The Sector Has Marked Challenges, but Many Opportunities for Growth
List of Tables
Table 2.1 Prominent Population-based Biobanks, 2010
Table 2.2 Prominent Disease-oriented Biobanks, 2010
Table 2.3 Some Guidelines and Recommendations for Biobanks, 2010
Table 2.4 Laws and Regulations for Biobank-based Research, Consent Requirements, and Privacy/ Data Protection, 2010
Table 3.1 Some Pharmaceutical and Biotechnology Companies with In-house Biobanks, 2010
Table 4.1 Prominent Companies in the Automated Liquid Handling Market, 2010
Table 4.2 Prominent Companies in Ultra-low Temperature Freezer Market, 2010
Table 4.3 Prominent LIMS Vendors, 2010
Table 4.4 Prominent Consumables Suppliers for Biobanking, 2010
Table 4.5 Prominent Biorepository Service Providers, 2010
Table 5.1 Estimated Number of Biobanks in Europe, 2010
Table 5.2 Overall Biobanking Market: Revenue Forecast, 2010-2017
Table 5.3 Overall Biobanking Market: Revenue Forecast, 2018-2025
Table 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2017
Table 6.2 Human Tissue Banking Market: Overall Revenue Forecast, 2018-2025
Table 6.3 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2010-2017
Table 6.4 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2018-2025
Table 6.5 Human Tissue Banking Market: Revenue Forecasts for Leading National Markets, 2010-2025
Table 6.6 Leading Companies in the World Biobanking Market, 2010
Table 6.7 Asterand: Revenue by Segment, 2008 and 2009
Table 6.8 Asterand: Revenue by Geographical Area, 2008 and 2009
Table 7.1 Stem Cell Banking: Revenue Forecast, 2010-2017
Table 7.2 Stem Cell Banking: Revenue Forecast, 2018-2025
Table 7.3 Prominent Stem Cell Banks Serving the Research Community, 2010
Table 7.4 Prominent Companies in the Cord Blood Banking Market, 2010
Table 9.1 SWOT Analysis of the Biobanking Sector, 2010
Table 9.2 Information for a Biobank Donor, 2010
List of Figures
Figure 2.1 Processes Involved in Biobanking, 2010
Figure 2.2 Classification of Biobanks, 2010
Figure 3.1 Biobanking and Pharmaceutical Development, 2010
Figure 4.1 Biobanking Industry: Value Chain Model, 2010
Figure 4.2 Functions of LIMS, 2010
Figure 5.1 Overall Biobanking Market: Revenue Forecast, 2010-2025
Figure 6.1 Human Tissue Banking Market: Overall Revenue Forecast, 2010-2025
Figure 6.2 Human Tissue Banking Market: Revenue Forecasts by Type of Biobank, 2010-2025
Figure 6.3 Human Tissue Banking: Market Shares by Type of Biobank, 2010
Figure 6.4 Human Tissue Banking: Market Shares by Type of Biobank, 2025
Figure 6.5 Human Tissue Banking: Market Shares for Leading National Markets, 2010
Figure 6.6 Human Tissue Banking: Market Shares for Leading National Markets, 2015
Figure 6.7 Human Tissue Banking: Market Shares for Leading National Markets, 2020
Figure 6.8 Human Tissue Banking: Market Shares for Leading National Markets, 2025
Figure 6.9 Commercial Sourcing of Biological Samples, 2010
Figure 6.10 Commercial Banking of Biological Samples, 2010
Figure 6.11 Asterand: Revenues, 2008 and 2009
Figure 6.12 Asterand: Revenue Shares by Region of Destination, 2009
Figure 6.13 Asterand: Revenue Shares by Region of Origin, 2009
Figure 7.1 Stem Cell Banking: Revenue Forecast, 2010-2025
Companies Listed
Abcellute
Abgene
Adnexus Therapeutics
AFNOR Groupe
AKH Biobank
AlloSource
American National Bioethics Advisory Commission
American Type Culture Collection
Amgen
Analytical Biological Services
ARCH Venture Partners
Asterand
Asterand UK Limited
Asterand
AstraZeneca
Australasian Biospecimen Network (ABN)
Autoscribe
AXM Pharma
Bayer-Schering
Beckman Coulter
Biobank Ireland Trust
Biobank Japan
Biobanking and Biomolecular Resources Research Infrastructure (BBMRI)
BioFortis
Biogen Idec
BioLife Solutions
Biomatrica
Biopta
BioRep
BioSeek
BioServe
BioStorage LLC
BioStorage Technologies
BrainNet Europe
Caliper LifeSciences
Canadian Partnership for Tomorrow
CARTaGENE
Cellgene Corporation
Cells4Health
Chemagen
CLB/ Amsterdam Medical Center
CorCell
Cord Blood America
Cord Blood Registry
CordLife
Cordon Vital (CBR)
Coriell Institute for Medical Research
Council of Europe (CoE)
Covance
Cryo Bio System
Cryo-Cell International
Cryometrix
Cryo-Save
Cureline
Cybrdi
Danubian Biobank Foundation
deCODE Genetics
Department of Health (DoH)
Department of Transportation (DOT)
Draper Laboratory
EGeen
Eli Lilly
Eolas Biosciences
Estonian Genome Project
EuroBioBank
European Commission (EC)
European Health Risk Monitoring (EHRM)
European Medicines Agency (EMA/EMEA)
European Union Group on Ethics (EGE)
Fisher BioServices
Fondazione I.R.C.C.S. Istituto Neurologico C. Besta
Food and Drug Administration (US FDA)
Foundation for the National Institutes of Health
Fundacion Istituto Valenciano de Oncologia
Fundeni Clinical Institute
Genentech
Generation Scotland
GeneSaver
GeneSys
Genetic Association Information Network (GAIN)
Genizon Biosciences
Genome Quebec Biobank
GenomEUtwin
Genomic Studies of Latvian Population
GenVault
German Dementia Competence Network
GlaxoSmithKline (GSK)
H. Lee Moffitt Cancer Center and Research Institute
Hamilton
Hopital Necker Paris – Necker DNA Bank
Human Tissue Authority (HTA)
Hungarian Biobank
HUNT, Norway
ILSBio LLC
Inbiobank
Indivumed
INMEGEN
Institut National de la Sante et de la Recherche Medicale (INSERM)
Integrated BioBank of Luxembourg
International Agency for Research on Cancer (IARC)
International Air Transport Association (IATA)
International Organization for Standardization (ISO)
International Society for Biological and Environmental Repositories (ISBER)
International Stem Cell Corporation
Kaiser Permanente
KORA-gen
LabVantage Solutions
LabWare
Leiden University Medical Center
LifebankUSA
LifeGene
LifeStem
Malaysian Cohort Project
Matrical Biosciences
Matrix
Medical Research Council (MRC)
Medical University of Gdansk
Merck & Co.
Merck Sharp & Dohme Limited (MSD)
Merck-Serono
Micronic
Milennium (Takeda Oncology Company)
MVE-Chart
National Cancer Institute (NCI)
National DNA Bank (US)
National Human Genome Research Institute (NHGRI)
National Institute of Environmental Health
National Institutes of Health (NIH)
National Public Health Institute
National Research Ethics Service (NRES)
NeoCodex
NeoStem
Neuromuscular Bank of Tissues and DNA Samples
New Brunswick Scientific
NEXUS Biosystems
Northwest Regional Development Agency
Novacare Bio-Logistics
Novartis
NUgene Project
Ocimum Biosolutions
Office of Biorepositories and Biospecimen Research (OBBR)
OnCore UK
Organisation for Economic Co-operation and Development (OECD)
OriGene
Oxagen
Pacific Bio-Material Management
PathServe
Perkin Elmer
Pfizer
Pharmagene Laboratories Trustees Limited
Polaris Ventures
Pop-Gen (University Hospital Schleswig-Holstein)
PrecisionMed
Prevention Genetics
ProMedDx
Promoting Harmonisation of Epidemiological Biobanks in Europe (PHOEBE)
ProteoGenex
Public Population Projects in Genomics (P3G Consortium)
Qiagen
RAND Corporation
REMP
Reproductive Genetics Institute (RGI)
Research Centre of Vascular Diseases, University of Milan
Rhode Island BioBank, Brown University
Roche
RTS Life Science
Saga Investments LLC
Sanofi-Aventis
SANYO Biomedical
Scottish Government
Seattle Genetics
SeqWright DNA Technology Services
SeraCare Life Sciences
Singapore Tissue Network
StarLIMS
Steelgate
Stem Cell Authority
Stem Cells for Safer Medicine (SC4SM)
Stem Cells Research Forum of India
Stemride International
Taiwan Biobank
Taizhou Biobank
TAP
Tecan
The Automation Partnership
The Sorenson Molecular Genealogy Foundation (SMGF)
Thermo Fisher Scientific
Tissue Solutions
Titan Pharmaceuticals
Trinity Biobank
Tumorotheque Necker-Entants Malades
UK Biobank
UK Stem Cell Bank
UmanGenomics
Umea University
University Hospital Angers
University Medical Center Gent
University of Massachusetts Stem Cell Bank
University of Tuebingen, Department of Medical Genetics
US Biomax
Vasterbotten County Council
ViaCord
Wellcome Trust
Wellcome Trust Case-Control Consortium (WTCCC)
Western Australian Genome Health Project
Wheaton Science International
Wisconsin International Stem Cell (WISC) Bank
World Health Organization (WHO)
To order this report:
Blood Supply, Tissue Banking and Transplantation Industry: Biobanking for Medical R&D: Technology and Market 2010-2025
Blood Supply, Tissue Banking and Transplantation Business News
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT: |
|
Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article